Home > Healthcare > Medical Devices > Diagnostic Devices > Liquid Biopsy Market

Liquid Biopsy Market Size

  • Report ID: GMI3775
  • Published Date: Nov 2021
  • Report Format: PDF

Liquid Biopsy Market Size

Liquid Biopsy Market size exceeded USD 1.2 billion in 2020 and is anticipated to grow at a CAGR of over 29.7% between 2021 and 2027. Growing awareness regarding causes and diagnosis of cancer with several awareness campaigns will contribute to the demand for liquid biopsy in the coming years.

 

 

Authors: Mariam Faizullabhoy

Frequently Asked Questions (FAQ) :

Market size of liquid biopsy surpassed USD 1.2 billion in 2020 and is expected to expand at a CAGR of 29.7% from 2021 to 2027 with increasing awareness regarding the causes and diagnosis of cancer.

The kits & reagents accounted for over 50% of the revenue share in 2020 and will grow with soaring adoption of liquid biopsy in research institutes and reference laboratories.

The lung cancer is poised to exhibit a growth rate of 29.7% up to 2027 owing to the growing adoption of unhealthy lifestyle, comprising tobacco consumption and smoking, and a subsequent increase in the incidence rate.

North America market size recorded 31% of the global industry revenue in 2020 and will rise with the availability of highly advanced infrastructure and faster adoption of advanced methods.

Major players across the industry comprise Guardant Health, Inc., F. Hoffmann-La Roche Ltd., Lucence Health Inc., Genetics, Inc., BIOCEPT, Inc., and others.

Liquid Biopsy Market Scope

Buy Now


Premium Report Details

  • Base Year: 2020
  • Companies covered: 15
  • Tables & Figures: 170
  • Countries covered: 14
  • Pages: 130
 Download Free Sample